Of the common PDA drivers, mutations Kras and Trp53 were the only detectable oncogenic events across lesions at different stages of the disease with the exception of the LOH affecting Trp53 in poorly-differentiated and metastatic tumours. This evidence concerns the gene KRAS and Patent ductus arteriosus.